DSC Advisors L.P. cut its holdings in Neos Therapeutics Inc (NASDAQ:NEOS) by 36.7% during the fourth quarter, according to its most recent Form 13F filing with the SEC. The fund owned 661,045 shares of the company’s stock after selling 382,725 shares during the period. Neos Therapeutics accounts for about 3.9% of DSC Advisors L.P.’s portfolio, making the stock its 9th largest holding. DSC Advisors L.P. owned approximately 2.28% of Neos Therapeutics worth $6,743,000 at the end of the most recent quarter.
A number of other institutional investors and hedge funds have also added to or reduced their stakes in the stock. JPMorgan Chase & Co. purchased a new stake in Neos Therapeutics in the third quarter valued at approximately $120,000. Paloma Partners Management Co purchased a new stake in Neos Therapeutics in the fourth quarter valued at approximately $125,000. New York State Common Retirement Fund raised its position in Neos Therapeutics by 67.3% in the third quarter. New York State Common Retirement Fund now owns 17,400 shares of the company’s stock valued at $159,000 after purchasing an additional 7,000 shares during the period. Alliancebernstein L.P. purchased a new stake in Neos Therapeutics in the second quarter valued at approximately $161,000. Finally, Brandywine Global Investment Management LLC purchased a new stake in Neos Therapeutics in the fourth quarter valued at approximately $179,000. Hedge funds and other institutional investors own 49.33% of the company’s stock.
Shares of Neos Therapeutics Inc (NEOS) opened at $8.80 on Wednesday. Neos Therapeutics Inc has a 12-month low of $6.30 and a 12-month high of $13.15. The company has a debt-to-equity ratio of 4.01, a quick ratio of 2.14 and a current ratio of 2.42.
Neos Therapeutics Profile
Neos Therapeutics, Inc is a pharmaceutical company. The Company is focused on developing, manufacturing and commercializing products utilizing its modified-release drug delivery technology platform. Its segment is engaged in the development, manufacturing and commercialization of pharmaceuticals. It has utilized its platform to develop its product for the treatment of attention deficit hyperactivity disorder (ADHD).
Receive News & Ratings for Neos Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Neos Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.